Inserm Transfert Initiative (ITI)

https://www.it-initative.fr

Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012. It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies' development. Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Natixis Venture Selection, Pfizer, Sanofi, SHAM, Shire, Sofinnova Partners. *

	Start	2005-01-01 established
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Tharaud, Cécile (INSERM 201403– CEO of Inserm Transfert Initiative before CEO of Inserm Transfert)

	Region	Paris
	Country	France
	Street	7 rue Watt
	City	75013 Paris
	Tel	+33-1-5503-0100
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for France (govt)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)